Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun...

Related Keywords

India ,United States ,Mumbai ,Maharashtra ,Washington ,America ,Sun Pharma ,Roger Tung ,Abhishek Sharma ,Janet Metz ,Abhay Gandhi ,Justine Koenigsberg ,Gaurav Chugh ,Concert Pharmaceuticals ,Twitter ,Sun Pharmaceutical Industries Ltd ,Nasdaq ,Foliage Merger Sub Inc ,Moelis Company ,Chestnut Partners Inc ,Concert Investor Relations Department ,Health Partners ,Drug Administration ,Davis Polk Wardwell ,Sun Pharmaceutical Industries Limited ,Exchange Commission ,Prnewswire Sun Pharmaceutical Industries Limited Reuters ,Sun Pharma Investor Relations Department ,Concert Pharmaceuticals Inc ,Goodwin Procter ,Adds Deuruxolitinib ,Potential Best In Class Oral ,Alopecia Areata ,Autoimmune Dermatological ,Global Infrastructure ,Provide Broad Access ,Global Dermatology Franchise ,Late Stage Product ,Significant Unmet ,Commence Tender Offer ,Acquire All Outstanding Shares ,Common Stock ,Cash Payment ,Equity Consideration ,Value Right ,Certain Time Based Net Sales ,Pharmaceutical Industries Limited ,North America ,New Drug Application ,Concert Board ,Davis Polk ,Chestnut Partners ,Sun Pharmaceutical Industries ,Foliage Merger Sub ,Tender Offer Statement ,Recommendation Statement ,Investor Relations Department ,Tender Offer ,Large Cross Sectional Survey Study ,Investigational Dermatology ,Cosmet Investig ,Pharmaceutical Industries ,